Wednesday, April 02, 2008 9:52:37 AM
Dew or Genisi:
I more-or-less
understand that GTC has a recombinant product as opposed to Kamada's plasma-derived AAT.
Is the posting of their news simply a prudent and valuable continuation of the "keeping track of the competition" strategy, or are you posting it because it might have immediate relevance to GTC's stock price or ongoing partnership discussions? If the latter, could you elaborate? TIA.
I more-or-less
understand that GTC has a recombinant product as opposed to Kamada's plasma-derived AAT. Is the posting of their news simply a prudent and valuable continuation of the "keeping track of the competition" strategy, or are you posting it because it might have immediate relevance to GTC's stock price or ongoing partnership discussions? If the latter, could you elaborate? TIA.
Join the InvestorsHub Community
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
